Lakefront Biotherapeutics N.V. Stock Analysis & AI Score
Lakefront Biotherapeutics N.V. (LKFT) has an ST Score of 74.6 (B+), driven by its Profitability (A+) and held back by its Valuation (C). Analysts rate it Buy with a $35.50 price target (+16.9% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Lakefront Biotherapeutics N.V. (LKFT) has an ST Score of 74.6 (B+), driven by its Profitability (A+) and held back by its Valuation (C). Analysts rate it Buy with a $35.50 price target (+16.9% upside).
- Strongest
- ProfitabilityA+
- Weakest
- ValuationC
All factor grades
- ProfitabilityA+
- Financial StrengthA+
- MomentumA
- GrowthA
- ForecastB+
- ValuationC
- Piotroski4/9
Contact
LKFT stock: frequently asked questions
What is LKFT's ST Score?
Lakefront Biotherapeutics N.V. (LKFT) has an ST Score of 74.6 (B+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is LKFT a buy, hold, or sell?
Analysts rate LKFT a Buy, with a price target of $35.50 (+16.9% vs the current price). Our ST Score grades it B+ (74.6/100). The ST Score is a data-driven signal, not a recommendation.
What are LKFT's factor grades?
Valuation C, Profitability A+, Financial Strength A+, Momentum A, Growth A, Forecast B+.
What is LKFT's valuation grade?
Lakefront Biotherapeutics N.V. (LKFT) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is LKFT's growth grade?
Lakefront Biotherapeutics N.V. (LKFT) earns a growth grade of A, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is LKFT's profitability grade?
Lakefront Biotherapeutics N.V. (LKFT) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is LKFT's financial strength grade?
Lakefront Biotherapeutics N.V. (LKFT) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for LKFT?
The average analyst price target for Lakefront Biotherapeutics N.V. (LKFT) is $35.50 from 2 analysts, which is +16.9% versus the recent price of $30.36.
What is LKFT's Piotroski score?
Lakefront Biotherapeutics N.V. (LKFT) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.